Supreme Court rejects pharma challenges against CMS drug price negotiating powers

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Cancer Policy

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

Guest Editorial

Most Favored Nation drug pricing could put China on top

China’s biotech sector is rapidly becoming a global innovation powerhouse. In oncology alone, Chinese licensing deals reached $30 billion in 2024—triple the United States’ output. Nearly a third of the world’s clinical trials now take place in China.

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

The Centers for Medicare & Medicaid Services has proposed a rule to update Medicare payments for hospice care in the next fiscal year, which begins on Oct. 1.

Trump imposes up to 100% tariff on some brand name pharmaceutical companies

President Donald Trump has imposed a 100% tariff on drugmakers that have not struck a deal with the president to lower the U.S. drug prices of patented pharmaceutical products and ingredients.

April 03, 2026

Vol.52 No.13

By Claire Marie Porter

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

YOU MAY BE INTERESTED IN

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

Most Favored Nation drug pricing could put China on top

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

Trump imposes up to 100% tariff on some brand name pharmaceutical companies

Renew today!

Subscriber content

Never miss an issue!

Login